Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 92Breast Neoplasms 69Prostatic Neoplasms 33Triple Negative Breast Neoplasms 32Neoplasms 26Fallopian Tube Neoplasms 25Neoplasm Metastasis 21Endometrial Neoplasms 19Pancreatic Neoplasms 18Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 12Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Sarcoma 9Recurrence 9Lung Neoplasms 9Fanconi Anemia, Complementation Group D1 9Squamous Cell Carcinoma of Head and Neck 8Glioma 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Colorectal Neoplasms 6Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Solid Tumors 4Osteosarcoma 4

Interventions

olaparib 1cabazitaxel 1Prednisone 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Cancer, Hereditary, 7 × olaparib × Clear all
NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
96 enrolled
Genitourinary

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡